Award
CanadaBuys #E60PH-22HEAB
Amend 006 - Hepatitis A and B Adult and Pediatric - GlaxoSmithKline Inc.
Recipient
GlaxoSmithKline Inc.
Award Amount
$17,340,563.00
Ceiling
$17,340,563.00
Awarded
March 03, 2022
Identifier
E60PH-22HEAB
Contract amendment awarded to GlaxoSmithKline Inc. for Hepatitis A and B vaccines with a total value of CAD 17,340,563.63 over 48 months.
Description
This contract amendment is for Hepatitis A and B vaccines provided by GlaxoSmithKline Inc. The contract duration is 48 months from 2022/03/03 to 2026/03/31 with a total value of CAD 17,340,563.63. The contract is awarded under exclusive rights as per various trade agreements.